61 completed, 34 active not recruiting, 32 recruiting, 28 terminated. 119 Phase 2, 60 Phase 1, 19 Phase 3, 4 Early Phase 1, 4 Phase 4.
Follow niraparib: new trials by email Literature Review of niraparib trials Research Report on niraparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating Safety, Tolerability, and Metabolism of Niraparib Niraparib - Ovarian Cancer | Phase 4 | Recruiting | University of Miami | 70 | 2026-07-28 | 2026-08-05 |
| Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations Androgen Deprivation Therapy (ADT), Niraparib/Abiraterone Acetate DAT, Abiraterone Acetate - Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation | Phase 2 | Withdrawn | Qian Qin | 2025-10-01 | 2026-04-08 | |
| A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours LM-2417, Docetaxel, Toripalimab/Tirelizumab - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | LaNova Medicines Limited | 320 | 2025-09-17 | 2026-08-28 |
| Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer Zejula (Niraparib) - Advanced Ovarian Cancer | Not yet recruiting | Clinica Universidad de Navarra, Universidad de Navarra | 120 | 2025-07-25 | 2025-07-11 | |
| Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 3 | Recruiting | Imunon | 500 | 2025-07-09 | 2026-10-30 |
| Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy Niraparib, FOLFIRI, Ipilimumab - Pancreatic Adenocarcinoma Metastatic | Phase 2 | Recruiting | Abramson Cancer Center at Penn Medicine | 68 | 2025-05-07 | 2026-10-13 |
| Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer Niraparib/Abirate rone acetate fixed-dose combination, Prednisone - Prostate Cancer, Castrate Resistant Prostate Cancer | Phase 2 | Withdrawn | Latin American Cooperative Oncology Group | 2025-04-30 | 2025-09-29 | |
| A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer Niraparib - Ovarian Neoplasms | Phase 4 | Not yet recruiting | GlaxoSmithKline | 67 | 2025-04-22 | 2025-03-21 |
| Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer Biopsy, Biospecimen Collection, Niraparib - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2025-04-18 | 2025-05-23 | |
| Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers Niraparib, Dostarlimab - MMR-D/MSI-H Colorectal Cancers | Phase 2 | Withdrawn | Ibrahim Halil Sahin | 2025-01-31 | 2025-02-03 | |
| Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression Niraparib oral tablets - Ovarian Cancer, Oligometastatic Disease | Phase 2 | Recruiting | MedSIR | 30 | 2024-12-03 | 2026-04-22 |
| Real-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian Cancer Niraparib (Tablet) - Ovarian Cancer | Recruiting | Fudan University | 1920 | 2024-12-01 | 2026-08-24 | |
| Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) Tuvusertib (M1774), Niraparib, Lartesertib (M4076) - Ovarian Cancer | Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 63 | 2024-10-30 | 2026-09-14 |
| Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study. Niraparib 200/300 MG - Ovarian Cancer | Recruiting | Pomeranian Medical University Szczecin | 300 | 2024-09-02 | 2024-10-23 | |
| Niraparib and Temozolomide in Patients Glioblastoma Temodal, Niraparib - Glioma, Malignant | Phase 1 / Phase 2 | Not yet recruiting | Armando Santoro, MD | 86 | 2024-09-01 | 2024-08-30 |
| Personalized Medicine for Advanced Biliary Cancer Patients Futibatinib, Ivosidenib, Zanidatamab - Biliary Tract Neoplasms | Phase 3 | Recruiting | UNICANCER | 800 | 2024-07-18 | 2026-05-19 |
| SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy Niraparib oral capsule, SBRT - Ovarian Cancer Recurrent | Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 42 | 2024-06-20 | 2026-07-13 |
| A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma Niraparib, Temozolomide - Glioblastoma, GBM | Phase 3 | Active not recruiting | Ivy Brain Tumor Center | 450 | 2024-06-19 | 2026-07-01 |
| Niraparib in High-grade Endometrial Cancer Trial Niraparib oral capsule - Endometrial Cancer, Serous Adenocarcinoma | Early Phase 1 | Withdrawn | Sir Mortimer B. Davis - Jewish General Hospital | 2024-05-01 | 2024-12-19 | |
| High-Risk Metachronous Oligometastatic Prostate Cancer Trial niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT) - Prostate Cancer, Oligometastatic Disease | Phase 2 | Active not recruiting | University of Maryland, Baltimore | 88 | 2024-04-17 | 2026-05-06 |
Showing 20 of 202. Sign in to see all of them.
Ovarian Neoplasms (70) · Breast Neoplasms (21) · Neoplasms (21) · Fallopian Tube Neoplasms (18) · Prostatic Neoplasms (15) · Neoplasm Metastasis (9) · Carcinoma, Ovarian Epithelial (8) · Endometrial Neoplasms (8) · Pancreatic Neoplasms (8) · Glioblastoma (7) · Triple Negative Breast Neoplasms (6) · Lung Neoplasms (5) · Glioma (4) · Small Cell Lung Carcinoma (4) · Carcinoma (3)
Tesaro, Inc. (23) · GlaxoSmithKline (6) · Janssen Research & Development, LLC (6) · Massachusetts General Hospital (6) · M.D. Anderson Cancer Center (5) · Takeda (4) · ARCAGY/ GINECO GROUP (3) · Abramson Cancer Center at Penn Medicine (3) · EMD Serono Research & Development Institute, Inc. (3) · Hoffmann-La Roche (3) · University Health Network, Toronto (3) · University of Oklahoma (3) · Xiaoxiang Chen (3) · Dana-Farber Cancer Institute (2) · Grupo Español de Investigación en Cáncer de Ovario (2)
United States (95) · Spain (30) · France (29) · Italy (26) · United Kingdom (25) · China (24) · Canada (22) · Belgium (19) · Germany (15) · Netherlands (14) · Denmark (11) · Israel (11) · Norway (11) · Poland (11) · Sweden (9)
Xiaoxiang Chen, MD,PhD (3) · Lingying Wu (2) · Nader Sanai, MD (2) · Albert Font, MD (1) · Alberto Puccini (1) · Alberto Sobrero (1) · Alexandra Zimmer, M.D. (1) · Alice Ho, MD (1) · Amit M Oza, M.D. (1) · Amit Oza, MD (1)
PMID 39019698, PMID 40016438, PMID 37185961, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 23524863, PMID 23810788, PMID 27406346, PMID 27406347, PMID 28851423, PMID 29767688, PMID 30026000, PMID 30307465, PMID 31173551, PMID 31194225, PMID 31194228, PMID 31375879, PMID 31439812, PMID 31474354, PMID 31518175, PMID 31562799, PMID 32031889, PMID 32053137, PMID 32193378, PMID 32319233, PMID 32379297, PMID 32450725, PMID 32586393, PMID 32701140, PMID 32981695, PMID 33289920, PMID 33318079, PMID 33327047, PMID 33470063, PMID 33515503, PMID 33754187, PMID 34083331, PMID 34324028, PMID 34478166, PMID 34529000, PMID 34607820, PMID 34741021, PMID 34904813, PMID 35086719, PMID 35131040, PMID 35157829, PMID 35170751, PMID 35317973
2023 (9), 2017 (6), 2018 (4), 2016 (2), 2019 (2), P30CA033572 (1), P30CA093373 (1), P30CA138292 (1), U10CA180868 (1)